Summary:
- This article details the Phase 3 clinical trial results for mRNA-1345, Moderna’s investigational respiratory syncytial virus (RSV) vaccine.
- It highlights the vaccine's efficacy in preventing RSV-associated lower respiratory tract disease in older adults, demonstrating a statistically significant reduction in disease incidence.
- The report provides critical data on the safety profile and immunogenicity of the mRNA-based vaccine platform, which is essential for ongoing developments in infectious disease prophylaxis.